Unnamed: 0,title,date,stock,sentiment
266811.0,Chimerix Q1 EPS $(0.170) Up From $(0.350) YoY,2020-05-07 07:27:00-04:00,CMRX,neutral
266812.0,Chomerix shares are trading higher after the company announced it has initiated its Phase 2/3 study of DSTAT in acute lung injury for patients with severe coronavirus.,2020-04-29 07:35:00-04:00,CMRX,negative
266813.0,Chimerix Reports Initiation Of Phase 2/3 Study Of DSTAT In Acute Lung Injury For Patients With Severe Coronavirus Infection,2020-04-29 07:11:00-04:00,CMRX,negative
266814.0,Chimerix shares are trading higher after the company received FDA clearance for rolling submission of New Drug Application for Brincidofovir as a medical countermeasure for smallpox.,2020-04-28 16:54:00-04:00,CMRX,positive
266815.0,Chimerix Receives FDA Clearance For Rolling Submission Of New Drug Application For Brincidofovir As A Medical Countermeasure For Smallpox,2020-04-28 16:34:00-04:00,CMRX,neutral
266816.0,Chimerix Q4 EPS $(0.06) Beats $(0.17) Estimate,2020-02-25 07:14:00-05:00,CMRX,neutral
266817.0,Chimerix Presents Updated Results From Phase 2 Clinical Trial Of DSTAT In Refractory Myelodysplastic Syndrome And Acute Myeloid Leukemia At American Society Of Hematology Annual Meeting,2019-12-10 07:35:00-05:00,CMRX,neutral
266818.0,"Chimerix Q3 EPS $(0.15) Beats $(0.22) Estimate, Sales $1.958M Beat $900K Estimate",2019-11-05 07:56:00-05:00,CMRX,neutral
266819.0,Chimerix Announces Co. Is Finalizing Animal Studies Of Brincidofovir As Smallpox Medical Countermeasure For Planned NDA,2019-08-08 08:38:00-04:00,CMRX,neutral
266820.0,"Chimerix Q2 EPS $(0.35) Beats $(0.37) Estimate, Sales $1.438M Beat $1.15M Estimate; Phase 3 Trial Of Cx-01 In Front-Line Acute Myeloid Leukemia Planned To Initiate In Mid 2020",2019-08-08 08:38:00-04:00,CMRX,neutral
266821.0,Chimerix Announces Exclusive Worldwide License Of Phase 3 Ready CX-01 For Development In Acute Myeloid Leukemia,2019-07-31 07:08:00-04:00,CMRX,positive
266822.0,"Chimerix Restructuring To Reduce Workforce By More Than 50%, Maintaining Key Capabilities And Preserving Capital For New Programs",2019-05-09 09:17:00-04:00,CMRX,neutral
266823.0,"Chimerix Reports Positive Top-Line Survival Data From Pivotal Mouse Study As Key Milestone On Path To Smallpox Regulatory Submission; Plan To Focus On Execution Of Smallpox Program, Halting All Other Brincidofovir Development Activities",2019-05-09 09:16:00-04:00,CMRX,positive
266824.0,"Chimerix Q1 EPS $(0.35), Inline, Sales $2.356M Beat $1.5M Estimate",2019-05-09 08:21:00-04:00,CMRX,neutral
266825.0,"Chimerix Names Michael Sherman CEO, Michael Andriole Chief Business Officer",2019-04-08 17:01:00-04:00,CMRX,neutral
266826.0,"Citigroup Maintains Neutral on Chimerix, Lowers Price Target to $2",2019-03-06 08:48:00-05:00,CMRX,negative
266827.0,"Chimerix Q4 EPS $(0.29) Beats $(0.35) Estimate, Sales $4.864M Beat $880K Estimate",2019-03-05 07:14:00-05:00,CMRX,neutral
266828.0,Chimerix To Present Results From Post-Hoc Analysis Of Phase 3 Study Transplantation And Cellular Therapy Meetings Of ASBMT And CIBMTR 2019,2019-02-22 08:02:00-05:00,CMRX,neutral
266829.0,"Chimerix Reports Pres, CEO M. Michelle Berrey To Step Down; W. Garrett Nichols, Timothy Trost, Michael Alrutz Named To Newly-Created Office Of The CEO On Interim Basis",2019-02-06 08:08:00-05:00,CMRX,neutral
266830.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,CMRX,negative
266831.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,CMRX,negative
266832.0,"Chimerex, Inc. Q3 EPS $(0.33) Beats $(0.42) Estimate, Sales $369K Miss $970K Estimate",2018-11-08 08:58:00-05:00,CMRX,negative
266833.0,"Stocks Which Set New 52-Week Low Friday, October 26th",2018-10-29 09:56:00-04:00,CMRX,negative
266834.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,CMRX,negative
266835.0,"'6 kids dead, 12 sick in viral outbreak at New Jersey rehabilitation center' -ABC 7 NY",2018-10-23 15:00:00-04:00,CMRX,negative
266836.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,CMRX,negative
266837.0,Chimerix To Highlight Results From Multiple Ascending Dose Study Of IV Brincidofovir At IDWeek,2018-10-05 07:05:00-04:00,CMRX,positive
266838.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,CMRX,negative
266839.0,"Stocks Which Set New 52-Week Low Yesterday, September 12th",2018-09-13 10:19:00-04:00,CMRX,negative
266840.0,"Stocks Which Set New 52-Week Low Friday, September 7th",2018-09-10 16:38:00-04:00,CMRX,negative
266841.0,"Stocks Which Set New 52-Week Low Yesterday, September 6th",2018-09-07 16:49:00-04:00,CMRX,negative
266842.0,"Stocks Which Set New 52-Week Low Yesterday, September 4th",2018-09-05 10:26:00-04:00,CMRX,negative
266843.0,"Stocks Which Set New 52-Week Low Yesterday, August 16th",2018-08-17 10:40:00-04:00,CMRX,negative
266844.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,CMRX,negative
266845.0,"Chimerix Q2 EPS $(0.39) Beats $(0.44) Estimate, Sales $1.193M Beat $950K Estimate",2018-08-08 07:05:00-04:00,CMRX,neutral
266846.0,"Stocks Which Set New 52-Week Low Yesterday, August 6th",2018-08-07 11:28:00-04:00,CMRX,negative
266847.0,"Chimerix Reports Discovery, Demonstration Of Preclinical Activity Which Supports Ongoing Phase 1 Study Of New Antiviral Treatment, Prevention Of Norovirus",2018-06-12 07:03:00-04:00,CMRX,positive
266848.0,Chimerix Reports Received Orphan Drug Designation For Brincidofovir For Treatment Of Smallpox,2018-06-07 07:30:00-04:00,CMRX,neutral
266849.0,Traders Circulating Chimerix FDA Document Showing Orphan Designation For brincidofovir,2018-06-06 13:02:00-04:00,CMRX,neutral
266850.0,Chimerix To Address Congressional Subcommittee In Support Of Reauthorization OfPandemic And All-Hazards Preparedness Act (PAHPA),2018-06-05 17:30:00-04:00,CMRX,positive
266851.0,"Chimerix Q1 EPS $(0.42) Beats $(0.43) Estimate, Sales $790K Miss $1.1M Estimate",2018-05-07 07:08:00-04:00,CMRX,negative
266852.0,Chimerix Names Martha Demski Chair,2018-03-29 16:32:00-04:00,CMRX,neutral
266853.0,"Chimerix Reports Q4 EPS $(0.41) vs $(0.47) Est., Sales $1.8M vs $870K Est.",2018-03-01 07:15:00-05:00,CMRX,neutral
266854.0,JP Morgan Downgrades Chimerix to Underweight,2018-02-14 08:18:00-05:00,CMRX,positive
266855.0,"H.C. Wainwright Initiates Coverage On Chimerix with Buy Rating, Announces $10.00 Price Target",2018-02-02 07:53:00-05:00,CMRX,neutral
266856.0,"Chimerix Reports Initiation Of AdAPT Study For Oral Brincidofovir, Advances IV Brincidofovir To Patient Studies",2018-01-05 07:05:00-05:00,CMRX,neutral
266857.0,"Chimerix Reports Q3 EPS $(0.37) vs $(0.43) Est., Sales $897K vs $850K Est.",2017-11-08 07:13:00-05:00,CMRX,neutral
266858.0,"Chimerix Q2 EPS $(0.36) vs $(0.41) Est., Sales $675K vs $1.19M Est.",2017-08-07 07:16:00-04:00,CMRX,neutral
266859.0,"Chimerix Q1 EPS $(0.38) vs $(0.36) Est, Sales $1.08M vs $1.42M Est",2017-05-09 07:20:00-04:00,CMRX,neutral
266860.0,Chimerix Reports Q4 EPS $(0.32) vs. $(0.37) Est.,2017-03-02 07:03:00-05:00,CMRX,neutral
266861.0,UPDATE: Chimerix Says 'Mortality rates were lower in pediatric patients than in adult patients',2017-02-22 08:15:00-05:00,CMRX,negative
266862.0,Chimerix Reports Final Data from AdVise Trial of Brincidofovir: 'Results show higher survival rate in adenovirus-infected patients with a virologic response',2017-02-22 08:14:00-05:00,CMRX,neutral
266863.0,"Chimerix Reports Final Data Of Brincidofovir, Results Show Higher Survival Rate In Adenovirus-Infected Patients With Virologic Response To Brincidofovir",2017-02-22 08:12:00-05:00,CMRX,neutral
266864.0,"Barclays Downgrades Chimerix to Equal-weight, Lowers PT to $6.00",2016-02-23 03:51:00-05:00,CMRX,negative
266865.0,"Morgan Stanley Downgrades Chimerix to Underweight, Lowers PT to $5.00",2016-02-22 17:56:00-05:00,CMRX,negative
266866.0,Citigroup Downgrades Chimerix to Neutral,2016-02-22 07:40:00-05:00,CMRX,neutral
266867.0,"Empire Asset Management Terminates Sell Rating on Chimerix, Was Only Firm With A 'Sell' Ratings",2015-12-29 09:59:00-05:00,CMRX,positive
266868.0,"FBR Capital Downgrades Chimerix to Market Perform, Lowers PT to $14.00",2015-12-29 07:27:00-05:00,CMRX,negative
266869.0,"JP Morgan Downgrades Chimerix to Neutral, Lowers PT to $15.00, Sees Investors 'assigning little credit to brincidofovir'",2015-12-29 07:01:00-05:00,CMRX,positive
266870.0,"Cowen & Company Downgrades Chimerix to Market Perform, Lowers PT to $8.00",2015-12-28 13:40:00-05:00,CMRX,negative
266871.0,Brean Capital Downgrades Chimerix to Hold,2015-12-28 12:45:00-05:00,CMRX,neutral
266872.0,"UBS Initiates Coverage on Chimerix at Buy, Announces $55.00 PT",2015-12-17 08:34:00-05:00,CMRX,neutral
266873.0,"Janney Capital Earlier Initiated Coverage on Chimerix at Neutral, Announced $50.00 PT",2015-12-01 10:19:00-05:00,CMRX,neutral
266874.0,"Morgan Stanley Downgrades Chimerix to Equal-weight, Lowers PT to $50.00",2015-10-05 02:30:00-04:00,CMRX,negative
266875.0,Chimerix Prices 3.775M Share Offering @$39.75/Share,2015-06-10 21:43:00-04:00,CMRX,positive
266876.0,"Barclays Initiates Coverage on Chimerix at Overweight, Announces $55.00 PT",2015-03-04 06:44:00-05:00,CMRX,negative
266877.0,Chimerix Sees Full Enrollment of Suppress Trial in Summer 2015,2015-02-26 07:21:00-05:00,CMRX,neutral
266878.0,"JP Morgan Initiates Coverage on Chimerix at Overweight, Announces $51.00 PT",2015-02-03 05:45:00-05:00,CMRX,neutral
266879.0,"Chimerix, ContraVir Announce Strategic Collaboration on Antiviral Drug Candidate CMX157",2014-12-18 06:01:00-05:00,CMRX,neutral
266880.0,"Chimerex, Inc. Reports Q3 EPS of $(0.47); Revenue of $1.19M",2014-11-07 07:01:00-05:00,CMRX,neutral
266881.0,Chimerix Announces Brincidofovir Shows Potential Survival Benefit in Adenovirus Infection ,2014-10-08 06:31:00-04:00,CMRX,positive
266882.0,"UPDATE: Piper Jaffray Boosts Target on Chimerix from $33 to $37, Maintains Overweight",2014-10-02 10:13:00-04:00,CMRX,negative
266883.0,"Chimerex, Inc. Reports Q2 EPS of $(0.39) vs $(0.44) Est; Revenue of $919.0M vs $740.0K Est",2014-08-07 07:11:00-04:00,CMRX,neutral
266884.0,"Brean Capital Initiates Coverage on Chimerex, Inc. at Buy, Announces $33.00 PT",2014-06-23 16:32:00-04:00,CMRX,neutral
266885.0,Chimerix Prices 7.3M Share Offering at $14.22/Share,2014-05-21 05:23:00-04:00,CMRX,positive
266886.0,"Chimerex, Inc. Reports Q1 EPS of $(0.39) vs $(0.36) Est; Revenue of $780.0K vs $850.0K Est",2014-05-09 07:15:00-04:00,CMRX,neutral
266887.0,Chimerix Thanks FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection ,2014-03-15 10:30:00-04:00,CMRX,positive
266888.0,Chimerix Receives FDA Approval to Provide Brincidofovir to Josh Hardy ,2014-03-12 05:45:00-04:00,CMRX,positive
266889.0,"Chimerex, Inc. Reports Q4 EPS of $(0.31) vs $(0.41) Est; Revenue of $879.0K vs $1.19M Est",2014-03-07 07:06:00-05:00,CMRX,neutral
266890.0,"Canaccord Genuity Initiates Coverage on Chimerex, Inc. at Buy, Announces $34.00 PT",2014-02-13 08:22:00-05:00,CMRX,neutral
266891.0,"Piper Jaffray Initiates Coverage on Chimerex, Inc. at Overweight, Announces $33.00 PT",2013-11-26 16:24:00-05:00,CMRX,negative
266892.0,Chimerex Reports Q3 EPS of $(0.26) vs $(0.38) Est; Revenue of $912.0K vs $1.28M Est,2013-11-14 06:40:00-05:00,CMRX,neutral
266893.0,Chimerix Says CMX001-201 Met Primary Goal in CMV Viremia/Disease Cut,2013-09-26 08:12:00-04:00,CMRX,negative
266894.0,Chimerix Presents Positive Brincidofovir Adenovirus Phase 2 Results ,2013-09-11 07:05:00-04:00,CMRX,positive
266895.0,Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir,2013-09-09 07:07:00-04:00,CMRX,neutral
266896.0,Chimerix Announces Positive Top Line Data From CMX001 Phase 2 Adenovirus Study ,2013-08-14 06:08:00-04:00,CMRX,positive
266897.0,"Chimerex, Inc. Reports Q2 EPS of $(0.91) vs $(0.40) Est; Revenue of $808.0K vs $1.91M Est",2013-08-14 06:06:00-04:00,CMRX,neutral
266898.0,"Chimerix, BARDA Extend Collaboration on Development of CMX001 Against Smallpox ",2013-06-03 07:09:00-04:00,CMRX,positive
266899.0,"William Blair Initiated Coverage on Chimerex, Inc. at Outperform, Announced $28.00 PT",2013-05-07 11:01:00-04:00,CMRX,neutral
266900.0,"Cowen & Company Initiates Coverage on Chimerex, Inc. at Outperform",2013-05-06 09:37:00-04:00,CMRX,neutral
266901.0,"Lazard Capital Markets Initiates Coverage on Chimerex, Inc. at Buy, Announces $32.00 PT",2013-05-06 09:37:00-04:00,CMRX,neutral
266902.0,"Morgan Stanley Initiates Coverage on Chimerex, Inc. at Overweight, Announces $26.00 PT",2013-05-06 06:37:00-04:00,CMRX,negative
266903.0,Chimerix Files to Offer 6.1M Shares,2013-04-01 07:31:00-04:00,CMRX,positive
